MODERNA News & Analysis
We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.
Damien Conover | 24 September 2021
We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.
Karen Andersen, CFA | 07 May 2021
Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.
Morningstar.com.au | 19 January 2021
The plasma giant remains overvalued, according to Morningstar.
Emma Rapaport | 14 December 2020
Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.
Damien Conover, CFA | 24 November 2020
Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?
Karen Andersen, CFA | 22 July 2020